MP29-02 (Dymista®) - a new treatment option for allergic rhinitis

被引：2

作者：

Klimek, L. ^{[1
]}

Bachert, C. ^{[2
]}

Wagenmann, M. ^{[3
]}

Ring, J. ^{[4
]}

Pfaar, O. ^{[1
]}

机构：

[1] Zentrum Rhinol & Allergol, D-65183 Wiesbaden, Germany

[2] Univ Hosp, ENT Dept, Upper Airways Res Lab, Ghent, Belgium

[3] HNO Univ Klin, Dusseldorf, Germany

[4] Tech Univ Munich, Klin & Poliklin Dermatol & Allergol Biederstein, Munich, Germany

来源：

ALLERGOLOGIE | 2014年 / 37卷 / 02期

关键词：

allergic rhinitis; MP29-02; Dymista (R); azelastine; fluticasone propionate; AQUEOUS NASAL SPRAY; QUALITY-OF-LIFE; FLUTICASONE PROPIONATE; AZELASTINE HYDROCHLORIDE; INTRANASAL THERAPY; DOUBLE-BLIND; BURDEN; IMPACT; ASTHMA; SYMPTOMS;

D O I：

10.5414/ALX01606

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Introduction: Recent developments in drug research in the indication allergic rhinitis (AR) include the development of new compounds as well as new formulations of substances with synergistic effects. IVIP29-02 (Dymista (R)) is a novel drug for AR treatment consisting of a new intranasal formulation of the antihistamine azelastine hydrochloride (AZE) and the nasal glucocorticoid fluticasone propionate (FP). Methods: Based on a literature review we summarise the results of several clinical trials regarding efficacy and safety of MP29-02 compared to AZE and FP monotherapy and placebo. Results: Compared to AZE, FP, and placebo, MP29-02 has demonstrated a superior efficacy in regard to nasal and ocular symptoms. Patients with moderate-to-severe seasonal allergic rhinitis (SAR) treated with MP29-02 showed an up to 7 days faster response of nasal symptoms than AZE and up to 5 days faster than FP treatment. Also, in patients with chronic rhinitis, MP29-02 significantly improved nasal symptoms compared to the FP therapy. Discussion and conclusion: MP29-02 represents a novel and promising combination for the treatment of AR with superior efficacy over current first line therapies.

引用

页码：55 / 68

页数：14

共 50 条

[1] MP29-02: a breakthrough for the treatment of allergic rhinitis
Bernstein, Jonathan A.
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (15) : 2101 - 2113
[2] Onset of Action of MP29-02 in the Treatment of Seasonal Allergic Rhinitis
Bernstein, J. A.
Munzel, U.
Wheeler, W.
Sacks, H.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB199 - AB199
[3] MP29-02 in the Treatment of Nasal Symptoms of Seasonal Allergic Rhinitis
Carr, W.
Shah, S. R.
Wheeler, W.
Sacks, H.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB199 - AB199
[4] Novel efficacy parameters in allergic rhinitis management: results with a new allergic rhinitis therapy (MP29-02)
Carr, W.
Canonica, G. W.
Bachert, C.
Berger, W.
Munzel, U.
Bousquet, J.
[J]. ALLERGY, 2013, 68 : 186 - 187
[5] Short and Long-Term Safety Of MP29-02 In The Treatment Of Allergic Rhinitis
Berger, William
Bernstein, Jonathan A.
Ruiz, Nancy
Carr, Warner W.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB132 - AB132
[6] MP29-02 in the symptomatic treatment of seasonal allergic rhinitis - a comparative fall study
Carr, W.
Bernstein, J.
Sacks, H.
Price, D.
Bachert, C.
Bousquet, J.
[J]. ALLERGY, 2011, 66 : 356 - 356
[7] MP29-02 in the symptomatic treatment of seasonal allergic rhinitis - a comparative spring study
Meltzer, E.
Carr, W.
Sacks, H.
Price, D.
Bachert, C.
Bousquet, J.
[J]. ALLERGY, 2011, 66 : 131 - 131
[8] Real-world effectiveness of a new allergic rhinitis therapy (MP29-02)
Klimek, L.
Virchow, J. C.
Wahn, U.
Moesges, R.
Munzel, U.
Bachert, C.
[J]. ALLERGY, 2014, 69 : 322 - 322
[9] A new allergic rhinitis therapy (MP29-02*): all of ARIA in one puff
Moesges, R.
Klimek, L.
Baena-Cagnani, C.
Canonica, G. W.
[J]. ALLERGY, 2014, 69 : 323 - 324
[10] Time to response and onset of action of MP29-02 in the symptomatic treatment of seasonal allergic rhinitis
Bachert, C.
Car, W.
Sacks, H.
Munzel, U.
Maus, J.
Price, D.
Bousquet, J.
[J]. ALLERGY, 2011, 66 : 356 - 356

← 1 2 3 4 5 →